[go: up one dir, main page]

KR20020013563A - 수상세포로 항원을 전달하는 방법 - Google Patents

수상세포로 항원을 전달하는 방법 Download PDF

Info

Publication number
KR20020013563A
KR20020013563A KR1020017015173A KR20017015173A KR20020013563A KR 20020013563 A KR20020013563 A KR 20020013563A KR 1020017015173 A KR1020017015173 A KR 1020017015173A KR 20017015173 A KR20017015173 A KR 20017015173A KR 20020013563 A KR20020013563 A KR 20020013563A
Authority
KR
South Korea
Prior art keywords
antigen
cells
dendritic cells
cell
dendritic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020017015173A
Other languages
English (en)
Korean (ko)
Inventor
트라베르사리카티아
루쏘빈센조
보르디그논클라우디오
Original Assignee
제네라 에스.피.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제네라 에스.피.아. filed Critical 제네라 에스.피.아.
Publication of KR20020013563A publication Critical patent/KR20020013563A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4277—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020017015173A 1999-05-28 2000-05-24 수상세포로 항원을 전달하는 방법 Withdrawn KR20020013563A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A001180 1999-05-28
IT1999MI001180A IT1312570B1 (it) 1999-05-28 1999-05-28 Metodo per il traferimento di antigeni a cellule dendritiche.
PCT/EP2000/004712 WO2000073415A2 (fr) 1999-05-28 2000-05-24 Method de transfert d'antigenes dans des cellules dendritiques

Publications (1)

Publication Number Publication Date
KR20020013563A true KR20020013563A (ko) 2002-02-20

Family

ID=11383060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017015173A Withdrawn KR20020013563A (ko) 1999-05-28 2000-05-24 수상세포로 항원을 전달하는 방법

Country Status (10)

Country Link
EP (1) EP1185626A2 (fr)
JP (1) JP2003501019A (fr)
KR (1) KR20020013563A (fr)
CN (1) CN1187442C (fr)
AU (1) AU772703B2 (fr)
CA (1) CA2375349A1 (fr)
HK (1) HK1047131A1 (fr)
IL (1) IL146777A0 (fr)
IT (1) IT1312570B1 (fr)
WO (1) WO2000073415A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506596B2 (en) 2000-06-01 2003-01-14 Anna-Lena Spetz-Holmgren Method of DNA transfer
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
JP5020935B2 (ja) * 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1261847B (it) * 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
AU710783B2 (en) * 1994-06-14 1999-09-30 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo T cell activation by antigen-pulsed dendritic cells
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
ATE284707T1 (de) * 1997-08-22 2005-01-15 Science Park Raf S P A Tumorvakzinierung mittels verwendung autologer oder hla-verwandter antigen präsentierender zellen (apc), die mit einem tumorantigen sowie einem eine immunantwort hervorrufenden fremdantigen transduziert sind
WO1999042564A2 (fr) * 1998-02-20 1999-08-26 The Rockefeller University Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose

Also Published As

Publication number Publication date
CN1187442C (zh) 2005-02-02
AU772703B2 (en) 2004-05-06
IT1312570B1 (it) 2002-04-22
CA2375349A1 (fr) 2000-12-07
JP2003501019A (ja) 2003-01-14
HK1047131A1 (zh) 2003-02-07
IL146777A0 (en) 2002-07-25
CN1360628A (zh) 2002-07-24
WO2000073415A3 (fr) 2001-03-01
EP1185626A2 (fr) 2002-03-13
ITMI991180A1 (it) 2000-11-28
AU5215900A (en) 2000-12-18
WO2000073415A2 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
Reeves et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
US6030836A (en) Vitro maintenance of hematopoietic stem cells
US20040146492A1 (en) Methods and compositions for transforming dendritic cells and activating T cells
CA2479288C (fr) Procede de production de lymphocyte cytotoxique
AU730537B2 (en) Methods and compositions for transforming dendritic cells and activating T cells
CA2237698A1 (fr) Cellules genetiquement modifiees et leur utilisation dans la prophylaxie ou le traitement des maladies
Diao et al. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro
EP1666589B1 (fr) Procede de production de lymphocytes cytotoxiques
Yang et al. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells
Movassagh et al. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells
US20220160789A1 (en) DUAL ANTIGEN-RECOGNIZING iPS CELL-DERIVED CHIMERIC ANTIGEN RECEPTOR-T-CELL THERAPY
Roddie et al. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines
KR20020013563A (ko) 수상세포로 항원을 전달하는 방법
AU691501B2 (en) Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic T-cells
JP2001503976A (ja) 樹状細胞の成熟を補助する胸腺微環境の生産法
Akiyama et al. Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells
JP3962459B2 (ja) 造血幹細胞の分化・増殖調節方法
CN116970562B (zh) 一种抗原特异性t细胞的制备方法及其在免疫治疗中的应用
CN111166876A (zh) 一种免疫增强剂组合和编码核酸及其应用
Chischportich et al. Expression of the nlsLacz gene in dendritic cells derived from retrovirally transduced peripheral blood CD34+ cells
US5672493A (en) De novo induction of cells exhibiting characteristics of macrophages utilizing feline sarcoma virus
Nordon et al. Summary and Future Directions
Keoshkerian Gene therapy in acute non-lymphoblastic leukaemia
JP2002238552A (ja) ヒト血清アルブミンを用いたヒト末梢血単核球であるｃｄ１４＋細胞からの樹状細胞の調製方法
Stewart Adenovirus mediated immunogene therapy for the treatment of myeloma: Pre-clinical and clinical studies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20011127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid